Astellas Pharma Inc. (ALPMY) on Tuesday said the Phase 2 GLEAM study of zolbetuximab in metastatic pancreatic cancer failed to meet its primary endpoint of overall survival (OS).
The study was designed to evaluate the safety and efficacy of zolbetuximab in combination with gemcitabine plus nab-paclitaxel, compared with gemcitabine plus nab-paclitaxel alone, in patients with metastatic pancreatic adenocarcinoma.
The company noted that the impact of this result on Astellas' financial results for the fiscal year ending March 31, 2026, is expected to be minor.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.